Speaker
David R. Boulware MD, MPH
Professor of Medicine
Infectious Disease & International Medicine
Department of Medicine
University of Minnesota
Topic
Lessons from Virtual Trials in Time of a Pandemic: Minnesota Hydroxychloroquine Experience
Keywords
COVID-19; Patient-reported outcomes (PROs); Hydroxychloroquine; Epidemiology; Virtual trials
Key Points
- These virtual randomized controlled trials evaluated hydroxychloroquine as a post-exposure prophylaxis, pre-emptive early treatment, and pre-exposure prophylaxis for COVID-19.
- The trial of post-exposure prophylaxis employed patient-reported outcomes around COVID-19 symptoms and severity as well as side effects of hydroxychloroquine.
- Enrollment and screening of eligible participants was automated through a REDCap survey.
Discussion Themes
Being a virtual trial, were there concerns about practicing medicine “across state lines?”
There has been a mix of science and politics over the course of the COVID-19 pandemic. Because your trial had substantial media coverage, how did the publicity affect enrollment?
Many big strategy questions can be studied virtually. What changes do you see for trials during future pandemics?
Read reports of these virtual trials in New England Journal of Medicine, Annals of Internal Medicine, and the medRxiv preprint server.
Tags
#pctGR, @Collaboratory1